Discovery of novel, non-peptide HIV-1 protease inhibitors by pharmacophore searching

Journal of Medicinal Chemistry

Volumn 39, Issue 10, 1996, Pages 2047-2054

  Wang, Shaomeng ^a   Milne, G W A ^a   Yan, Xinjian ^a   Posey, Isadora J ^b   Nicklaus, Marc C ^a   Graham, Lisa ^c   Rice, William G ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF THE DISTRICT OF COLUMBIA   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DRUG CARRIER; NSC 117027; NSC 158393; NSC 32180; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG CONFORMATION; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROPHOBICITY; MOLECULAR MODEL; PREDICTION; PROTEINASE INHIBITION; VIRUS INHIBITION;

AMINO ACID SEQUENCE; BINDING SITES; CELL LINE; CRYSTALLOGRAPHY, X-RAY; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFORMATION SYSTEMS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA;

EID: 0029984203     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950874+     Document Type: Article

References (39)

1. (a) Gallo, R. C.; Sarin, P. S.; Gelmann, E. P.; Robert-Guroff, M.; Richardson, E.; Kalyanaraman, V. S.; Mann, D.; Sidhu, G. D.; Stahl, R. E.; Zolla-Prazner, S.; Leibowitch, J.; Popovic, M. Isolation of a T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 1983, 220, 865-867.
2. (b) Barre-Sinoussi, F.; Chermann, J. C.; Rey, F.; Nugeyre, M. T.; Chamaret, S.; Gruest, J.; Dauguet, C.; Axler-Blin, C.; Vezinet-Brun, F.; Rouzioux, C.; Rozenbaum, W., Montagnier, L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220, 868-871.
3. Jacks, T.; Power, M. D.; Masiarz, F. R.; Luciw, P. A.; Barr, P. J.; Varmus, H. E. Characterization of Ribosomal Frameshifting in HIV-1 gag-pol Expression. Nature 1988, 331, 280-283.
4. (a) Seelmeier, S.; Schidt, H.; Turk, V.; von der Helm, K. Human Immunodeficiency Virus has an Aspartic-type Protease that can be Inhibited by Pepstatin A. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 6612-6616.
5. (b) McQuade, T. J.; Tomasselli, A. G.; Liu, L.; Karacostas, V.; Moss, B.; Sawyer, T. K.; Heinrikson, R. L.; Tarpley, W. G. A. Synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.
6. (c) Ashorn, P.; McQuade, T. J.; Thaisrivongs, S.; Tomasselli, A. G.; Tarpley, W. G.; Moss, B. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 7472-7476.
7. Debouck, C.; Metcalf, B. W. Human immunodeficiency virus protease: A target for AIDS therapy. Drug. Dev. Res. 1990, 21, 1-17.
8. Thaisrivongs, S. Chapter 5, HIV protease inhibitors. Annu. Rep. Med. Chem. 1994, 17, 133-144.
9. (a) Plattner, J. J.; Norbeck, D. W. Obstacles to Drug Development from Peptide Leads. In Drug Discovery Technologies; Clark, C. R., Moss, W. H., Eds.; Ellis Horwood: Chichester, England, 1990; Chapter 5, pp 92-126.
10. (b) Olson, G. L.; Bolin, D. R.; Bonner, M. P.; Bös, M.; Cook, C. M.; Fry, D. C.; Graves, B. J.; Hatada, M.; Hill, D. E.; Kahn, M.; Madison, V. S.; Rusiecki, V. K.; Sarabu, R.; Sepinwall, J.; Vincent, G. P.; Voss, M. E. Concepts and progress in the development of peptide mimetics. J. Med. Chem. 1993, 36, 3039-3049.
11. (a) Romines, K. R.; Watenpaugh, K. D.; Tomich, P. K.; Howe, W. J.; Morris, J. K.; Lovasz, K. D.; Mulichak, A. M.; Finzel, B. C.; Lynn, J. C.; Horng, M. M.; Schwende, F. J.; Ruwart, M. J.; Zipp, G. L.; Chong, K. L.; Dolak, L. A.; Toth, L. N.; Howard, G. M.; Rush, B. D.; Wilkinson, K. F.; Possert, P. L.; Dalga, R. J.; Hinshaw, R. R. Use of medium-sized cycloalkyl rings to enhance secondary binding: Discovery of a new class of human immunodeficiency virus (HIV) protease inhibitors. J. Med. Chem. 1995, 38, 1884-1891.
12. (b) Thaisrivongs, S.; Tomich, P. K.; Watenpaugh, K. D.; Chong, K.-T.; Howe, W. J.; Yang, C.-P.; Strohbach, J. W.; Turner, S. R.; McGratch, J. P.; Bohanon, M. J.; Lynn, J. C.; Mulichak, A. M.; Spinelli, P. A.; Hinshaw, R. R.; Pagano, P. J.; Moon, J. B.; Ruwart, M. J.; Wilkinson, K. F.; Rush, B. D.; Zipp, G. L.; Dalga, R. J.; Schwende, F. J.; Howard, G. M.; Padbury, G. E.; Toth, L. N.; Piper, R. C.; Jeffrey, P. Structure-based design of HIV protease inhibitors: 4-Hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors. J. Med. Chem. 1994, 37, 3200-3204.
13. (c) Prasad, J. V. N. V.; Para, K. S.; Lunney, E. A.; Ortwine, D. F.; Dunbar, J. B.; Ferguson, D.; Tummino, P. J.; Hupe, D.; Tait, B. D.; Domagala, J. M.; Humblet, C.; Bhat, T. N.; Liu, B.; Guerin, D. M. A.; Baldwin, E. T.; Erickson, J. W.; Sawyer, T. K. Novel HIV-1 protease inhibitors. J. Am. Chem. Soc. 1994, 116, 6989-6990.
14. (d) Lunney, E. A.; Hagen, S. E.; Domagala, J. M.; Humblet, C.; Kosinski, J.; Tait, B. D.; Warmus, J. S.; Wilson, M.; Ferguson, D.; Hupe, D.; Tummino, P. J.; Baldwin, E. T.; Bhat, T. N.; Liu, B.; Erickson, J. W. A novel nonpeptide HIV-1 protease inhibitor: Elucidation of the binding mode and its application in the design of related analogs. J. Med. Chem. 1994, 37, 2664-2667.
15. (a) Martin, Y. C. 3D Database Searching In Drug Design. J. Med. Chem. 1992, 35, 2145-2154.
16. (b) Martin, Y. C.; Bures, M. G.; Willett, P. Searching Databases of Three-Dimensional Structures. In Reviews in Computational Chemistry; Lipkowitz, K. B., Boyd, D. B., Eds.; VCH Publishers: New York, 1990; pp 213-263.
17. (c) Sheridan, R. P.; Rusinko, A., III; Nilakantan, R.; Venkataraghavan, R. Searching for Pharmacophores in Large Coordinate Data Bases and Its Use in Drug Design. Proc. Natl. Acad. Sci. U.SA. 1989, 86, 8165-8169.
18. DesJarlais, R. L.; Seibel, G. L.; Kuntz, I. D.; Furth, P. S.; Alvarez, J. C.; Oritz De Montellano, P. R.; DeCamp, D. L.; Babe, L. M.; Craik, C. S. Structure-Based Design of Nonpeptide Inhibitors Specific for the Human Immunodeficiency Virus 1 Protease. Proc. Natl. Acad. Sci. U.SA. 1990, 87, 6644-6648.
19. Bures, M. G.; Hutchins, C. W.; Maus, M.; Kohlbrenner, W., Kadam, S.; Erickson, J. W. Using three-dimensional substructure searching to identify novel, nonpeptidic inhibitors of HIV-1 protease. Tetrahedron Comput. Methodol. 1990, 3, 673-680.
20. Lam, P. Y. S.; Jadhav, P. K.; Eyermann. C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, Y. N.; Chang, C.-H.; Weber, P. C.; Jackson, D. A.; Sharpe, T. R.; Erickson-Viitanen, S. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science 1994, 263, 380-384.
21. Milne, G. W. A.; Nicklaus, M. C.; Driscoll, J. S.; Wang, S.; Zaharevitz, D. W. The NCI Drug Information System 3D Database. J. Chem. Inf. Comput. Sci. 1994, 34, 1219-1224.
22. The National Cancer Institute Drug Information System was designed and built by NCI. See: Milne, G. W. A.; Miller, J. A.; et al. The NCI Drug Information System. Parts 1-6. J. Chem. Inf. Comput. Sci. 1986, 26, 154-197.
23. Chem-X is a product of Chemical Design Ltd., Roundway House, Cromwell Park, Chipping Norton, Oxon OX7 5SR, U.K. Chem-Model module is the model builder in Chem-X; see Chem-X reference manual for detail.
24. Wang, S.; Zaharevitz, D. W.; Sharma, R.; Marquez, V. E.; Lewin, N. E.; Du, L.; Blumberg, P. M.; Milne, G. W. A. The discovery of novel, structurally diverse protein kinase C agonists through computer 3D-database pharmacophore search. Molecular modeling studies. J. Med. Chem. 1994, 37, 4479-4489.
25. QUANTA/CHARMm, a molecular modeling system, as supplied by Molecular Simulations Inc., 16 New England Executive Park, Burlington, MA 01803.
26. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations. J. Comput. Chem. 1983, 4, 187-217.
27. Hosur, M. V.; Bhat, T. N.; Kempf, D. J.; Baldwin, E. T.; Liu, B.; Gulnik, S.; Wideburg, N. E.; Norbeck, D. W.; Appelt, K.; Erickson, J. W. Influence of stereochemistry on activity and binding modes for C-2 symmetry-based diol inhibitors of HIV-1 protease. J. Am. Chem. Soc. 1994, 116, 847-855.
28. (a) Hyland, L. J.; Tomaszek, T. A., Jr.; Meek, T. D. Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism. Biochemistry 1991, 30, 8454-8463.
29. (b) Yamazaki, T.; Nicholson, L. K.; Torchia, D. A.; Wingfield, P.; Stahl, S. J.; Kaufman, J. D.; Eyermann, C. J.; Hodge, C. N.; Lam, P. Y. S.; Ru, Y.; Jadhav, P. K.; Chang, C.-H.; Weber, P. C. NMR and X-rays evidence that the HIV protease catalytic aspartyl groups are protonated in the complex formed by the protease and a non-peptide cyclic urea-based inhibitor. J. Am. Chem. Soc. 1994, 116, 10791-10792.
30. Rice, W. G.; Schaeffer, C. A.; Graham, L.; Bu, M.; McDougal, L. S.; Orloff, S. L.; Villinger, F.; Young, M.; Oroszlan, S.; Fesen, M.; Pommier, Y.; Mendelyev, J.; Kun, E. The site of antiviral action of 3-nitrosobenzamide on the infectivity process of human immunodeficiency virus in human lymphocytes. Proc. Natl. Acad. Sci. U.SA. 1993, 90, 9721-9724.
31. Weislow, O. S.; Riser, R.; Fine, D. L.; Bader, J.; Shoemaker, R. H.; Boyd, M. R. New soluble-formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer Inst. 1989, 81, 577-586.
32. The reverse transcriptase was a gift of Steve Hughes, NCI-FCRDC, Frederick, MD.
33. Buckheit, R. W., Jr.; Hollingshead, M. G.; Germany-Decker, J.; White, E. L.; McMahon, J. B.; Allen, L. B.; Ross, L. J.; Decker, W. D.; Westbrook, L.; Shannon, W. M.; Weislow, O.; Bader, J. P.; Boyd, M. R. Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new normucleoside reverse transcriptase inhibitor. Antiviral Res. 1993, 21, 247-265.
34. Rice, W. G.; Supko, J. G.; Malspeis, L.; Buckheit, R. W., Jr.; Clanton, D. J.; Bu, M.; Graham, L.; Schaeffer, C. A.; Turpin, J. A.; Domagala, J.; Gogliotti, R.; Bader, J. P.; Halliday, S. M.; Coren, L.; Sowder, R. C.; Arthur, L. O.; Henderson, L. E. Inhibitors of HIV Nucleocapsid Protein Zinc Fingers as Candidates for the Treatment of AIDS. Science 1995, 270, 1194-1197.
35. Wlodawer, A.; Erickson, J. W. Structure-based inhibitor of HIV-1 protease. Annu. Rev. Biochem. 1993, 62, 543-585.
36. Such complex structures are found in the Protein Data Bank, which is maintained at the Brookhaven National Laboratory. See: Bernstein, F. C.; Koetzle, T. F.; Williams, G. J. B.; Meyer, E. F., Jr.; Brice, M. D.; Rodgers, J. R.; Kennard, O.; Shimanouchi, T.; Tasumi, M. The Protein Data Bank: a computer-based archival file for macromolecular structures. Arch. Biochem. Biophys. 1978, 185, 584-591.
37. Mazumder, A.; Pommier, Y. Private communication.
38. Nicklaus, M. C.; Wang, S.; Driscoll, J. S.; Milne, G. W. A. Conformational Changes of Small Molecules Binding to Proteins. Bioorg. Med. Chem. 1995, 3, 411-428.
39. Holloway, M. K.; Wai, J. M.; Halgren, T. A.; Fitzgerald, P. M. D.; Vacca, J. P.; Dorsey, B. D.; Levin, R. B.; Thompson, W. J.; Chen, L. J.; deSolms, S. J.; Gaffin, N.; Ghosh, A. K.; Giuliani, E. A.; Graham, S. L.; Guare, J. P.; Hungate, R. W.; Lyle, T. A.; Sanders, W. M.; Tucker, T. J.; Wiggins, W.; Wiscount, C. M.; Woltersdorf, O. W.; Young, S. D.; Darke, P. L.; Zugay, J. A. A Priori Prediction of the Activity for HIV-1 Protease Inhibitors Employing Energy Minimization in the Active Site. J. Med. Chem. 1995, 38, 305-317.